Bacillus-Calmette-Guérin plus mitomycin versus Bacillus-Calmette-Guérin alone for Bacillus-Calmette-Guérin–naïve non–muscle-invasive-bladder-cancer: A randomised phase 3 trial (ANZUP 1301)

BCG + MM was not proved superior to BCG alone, but required 39% fewer doses of BCG and fewer treatment discontinuations. These findings support consideration of BCG + MM as a pragmatic alternative to BCG alone, which could mitigate the global shortage of BCG.